Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, T-Cell, Cutaneous 7Lymphoma 7Sezary Syndrome 5Immunoblastic Lymphadenopathy 5Recurrence 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Mycosis Fungoides 4Melanoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Lymphocytic, Chronic, B-Cell 4Subcutaneous panniculitis-like T-cell lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Hodgkin Disease 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Skin Neoplasms 2Primary Myelofibrosis 2Neoplasms, Plasma Cell 2Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Myelomonocytic, Chronic 2

Interventions

pembrolizumab 24Nivolumab 23aldesleukin 21Cyclophosphamide 20Ipilimumab 17Interleukin-2 17fludarabine 15fludarabine phosphate 14cemiplimab 12Radiotherapy 7Fluorouracil 7Biopsy 7dabrafenib 6Surveys and Questionnaires 6Dacarbazine 6trametinib 5binimetinib 5Vemurafenib 5Temozolomide 5Surgical Procedures, Operative 5Sirolimus 5Radiation 5Blood Specimen Collection 5Aminolevulinic Acid 5sonidegib 4encorafenib 4Photochemotherapy 4Mohs Surgery 4HhAntag691 4Educational Status 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Skin Neoplasms × Prednisone × Dermatologic × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡